Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of RG3502 Plus RG1273 in HER2-Positive Breast Cancer
jRCT2080221197Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2010
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab emtansine and TrastuRel in breast cancer, sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
trastuzumab emtansineTrastuRel
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080221197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221197.